XML 107 R68.htm IDEA: XBRL DOCUMENT v3.21.1
5 Business combinations (Details Narrative) - BRL (R$)
R$ in Thousands
 12 Months Ended
Nov. 09, 2020
Nov. 04, 2020
Nov. 03, 2020
Jul. 20, 2020
May 05, 2020
Jan. 31, 2020
May 09, 2019
Apr. 03, 2019
Mar. 29, 2019
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Disclosure of detailed information about business combination [line items]                        
Net revenue                   R$ 1,201,191 R$ 750,630 R$ 333,935
Income loss before income taxes                   R$ 335,054 R$ 186,937 R$ 98,722
Guardaya [member]                        
Disclosure of detailed information about business combination [line items]                        
Description of acquiree                 Afya Brazil merged (i) BR Health, a wholly-owned subsidiary of Crescera that controls Guardaya and is one of Afya Brazil's shareholders; and (ii) Guardaya which owns 100% of Medcel Editora and CBB Web, resulting in the transfer to Afya Brazil of 100% of Medcel Editora and CBB Web shares. In connection with the transaction 15% of UEPC's shares were acquired. Afya Brazil issued 378,696 common shares as a consideration for the interest in BR Health and Guardaya. The fair value of the consideration given was R$ 259,113. This transaction was strategic to the Company and was accounted for under IFRS 3 – Business Combinations.      
Revenue of acquiree since acquisition date                 R$ 40,554      
Profit (loss) of acquiree since acquisition date                 5,786      
Transaction costs                 482      
Net revenue                 75,238      
Income loss before income taxes                 R$ 21,924      
FCMPB [member]                        
Disclosure of detailed information about business combination [line items]                        
Proportion of ownership interest in subsidiary 100.00%                      
Description of acquiree The total net purchase price of R$379,913 was adjusted to Rincreased by R$ 142 and income before income taxes for 2020 would have been decreased by R$ 46.$378,807 and is comprised of (i) R$189,913 paid in cash on the transaction closing date, and (ii) R$188,894 is payable in cash in four equal installments through 2024, adjusted by the CDI rate.                      
Transaction costs R$ 721                      
Net revenue 10,509                      
Income loss before income taxes R$ 3,570                      
MEDPHONE [member]                        
Disclosure of detailed information about business combination [line items]                        
Proportion of ownership interest in subsidiary   100.00%                    
Description of acquiree   The net purchase price was R$6,373 of which 100% was paid in cash on the closing of the operation. The purchase price was adjusted to R$6,409, this price adjustment of R$ 36 was paid on February 2, 2021.                    
Transaction costs   R$ 158                    
Net revenue   49                    
Income loss before income taxes   57                    
Increase in revenue   142                    
Decreased in income before income taxes   R$ 46                    
FESAR [member]                        
Disclosure of detailed information about business combination [line items]                        
Proportion of ownership interest in subsidiary     100.00%                  
Description of acquiree     The aggregate purchase price was R$260,836, including the CDI rate adjustment from the signing date and the real state of the operation, estimated at R$ 17,397, of which 100% was paid in cash on the closing of the operation. The purchase consideration was adjusted by R$1,569 and was paid on February 25, 2021.                  
Transaction costs     R$ 2,047                  
Net revenue     6,280                  
Income loss before income taxes     3,751                  
Increase in revenue     29,113                  
Increase in income before income taxes     R$ 14,918                  
PEBMED [member]                        
Disclosure of detailed information about business combination [line items]                        
Proportion of ownership interest in subsidiary       100.00%                
Description of acquiree       The original purchase price of R$ 132,900 was adjusted by R$ 30 and was comprised by: i) R$115,339 paid in cash on the acquisition date; and ii) R$ 17,531 was paid with Afya Brazil’s shares which were afterwards contributed to the Company in exchange of issuance of 141,976 of its own shares.                
Transaction costs       R$ 613                
Net revenue       17,535                
Income loss before income taxes       3,413                
Increase in revenue       17,452                
Decreased in income before income taxes       R$ 1,813                
UniSL [member]                        
Disclosure of detailed information about business combination [line items]                        
Proportion of ownership interest in subsidiary         100.00%              
Description of acquiree         The original purchase consideration of R$201,521 was adjusted by R$7,816, of which: (i) 70% is payable in cash on the transaction closing date, and (ii) 30% is payable in cash in three equal installments through 2023, adjusted by the CDI rate. The purchase consideration adjustment of R$7,816 will be deducted from the first installment due in May 2021.              
Transaction costs         R$ 1,666              
Net revenue         113,894              
Income loss before income taxes         30,648              
Increase in revenue         57,477              
Additional payment made         80,000              
Increase in income before income taxes         R$ 9,455              
UniRedentor [member]                        
Disclosure of detailed information about business combination [line items]                        
Proportion of ownership interest in subsidiary           100.00%            
Description of acquiree           The original purchase price of R$214,608, was adjusted by R$4,503 and was comprised by: i) R$114,607 paid in cash on the acquisition date; and ii) R$100,000 is payable in five equal installments from January 2021 to July 2024, adjusted by the CDI rate. The purchase consideration adjustment of R$4,503 will be deducted from the first installment due in January 2021            
Transaction costs           R$ 1,380            
Net revenue           10,509            
Income loss before income taxes           R$ 3,570            
Instituto de pesquisa e ensino medico do estado de minas gerais ltda. ("IPEMED") [member]                        
Disclosure of detailed information about business combination [line items]                        
Proportion of ownership interest in subsidiary             100.00%          
Description of acquiree             IPEMED is a post-secondary education institution with campuses located in the states of Bahia, Minas Gerais, Rio de Janeiro, São Paulo and in the Distrito Federal. It focuses on medical graduate programs. The purchase price was R$ 97,542, being: i) R$ 25,000 paid in cash as advance through April 2019; ii) R$ 27,239 paid in cash on the acquisition date; iii) R$45,303 payable in five annual installments due from February 2020 to February 2024 adjusted by the Interbank Certificates of Deposit ("CDI") rate. This transaction was strategic to the Company and was accounted for under IFRS 3 – Business Combinations.          
Purchase consideration transferred [1]             R$ 97,542          
Goodwill recognised [1]             87,647          
Revenue of acquiree since acquisition date             43,244          
Profit (loss) of acquiree since acquisition date             10,735          
Revenue of combined entity as if combination occurred at beginning of period             67,594          
Profit (loss) of combined entity as if combination occurred at beginning of period             6,808          
Cash paid [1]             52,239          
Payable in installments [1]             45,303          
Transaction costs [1]             R$ (180)          
Description of adjustment             R$45,303 payable in five annual installments due from February 2020 to February 2024 adjusted by the Interbank Certificates of Deposit ("CDI") rate.          
Instituto educacional santo agostinho s.a. ("FASA") [member]                        
Disclosure of detailed information about business combination [line items]                        
Proportion of ownership interest in subsidiary               90.00%        
Description of acquiree               The purchase price of R$ 201,565 is comprised by: i) R$ 102,330 paid in cash on the acquisition date; ii) R$ 39,695 payable in April 2020; iii) R$ 29,770 payable in April 2021; and iv) R$ 29,770 payable in April 2022, adjusted by the IPCA rate + 4.1% per year. This transaction was strategic to the Company and was accounted for under IFRS 3 – Business Combinations. There isare no contingent consideration associated with the acquisition of FASA.        
Purchase consideration transferred [2]               R$ 201,565        
Goodwill recognised [2]               58,903        
Revenue of acquiree since acquisition date               69,996        
Profit (loss) of acquiree since acquisition date               16,501        
Revenue of combined entity as if combination occurred at beginning of period               90,063        
Profit (loss) of combined entity as if combination occurred at beginning of period               16,872        
Cash paid [2]               102,330        
Payable in installments [2]               99,235        
Transaction costs [2]               R$ (1,887)        
Description of adjustment               IPCA rate + 4.1% per year        
[1] During the measurement period of the assets acquired and liabilities assumed at the fair value, the Company has identified R$1,320 of indemnification assets, related to the acquisition of IPEMED.
[2] During the measurement period, the purchase consideration for the acquisition of FASA was adjusted by R$3,022 as a result of purchase price adjustments. Accordingly, goodwill was updated to R$58,903.